As BRCA1 or RAD51C gene silencing through promoter methylation has been detected in ovarian and breast tumours [53] and has been associated with HRD cases [54], a potential mechanism of resistance to PARPi in these tumours would involve gene re-expression. The gene discussed is RAD51C; the disease is neoplasm.